“Ivan is an incredible teammate and natural leader as well as one of the most hard-working people I've ever had the pleasure of meeting. We were teammates in an Engineering Entrepreneurship class, and over the course of a semester, Ivan effortlessly led and supported our team in building out the framework, product demo, value proposition, implementation timeline, and beta test for a startup idea that we successfully pitched to Jon Burgstone, the founder of Berkeley's CET. He is an extremely intelligent and charismatic person, and I am very excited to see the great work he will do as well as would love to work with him again in the future.”
About
Investor & advisor in early stage companies
Experience & Education
Publications
-
Simultaneous Expression of Displayed and Secreted Antibodies for Antibody Screen
PLOS ONE
The display of full-length antibody on the cell surface was achieved by fusing a transmembrane domain of the platelet-derived growth factor receptor (PDGFR) to the C-terminus of the heavy chain constant region. We also incorporated a furin cleavage site between the constant region and PDGFR transmembrane domain to obtain secreted antibodies. As a result, antibodies can be expressed simultaneously on the cell surface in a membrane-anchored version for screening and selecting through…
The display of full-length antibody on the cell surface was achieved by fusing a transmembrane domain of the platelet-derived growth factor receptor (PDGFR) to the C-terminus of the heavy chain constant region. We also incorporated a furin cleavage site between the constant region and PDGFR transmembrane domain to obtain secreted antibodies. As a result, antibodies can be expressed simultaneously on the cell surface in a membrane-anchored version for screening and selecting through fluorescence-activated cell sorting (FACS) analysis, as well as in conditioned medium in a secreted version for function analysis.
Other authors -
Four-way ligation for construction of a mammalian cell-based full-length antibody display library
Acta Biochimica et Biophysica Sinica
A unique four-way ligation strategy was developed for rapid construction of a full-length antibody library. A mammalian expression vector was constructed that contained dual mammalian expression cassettes and sequences recognized by the unique restriction enzymes BsmBI, BstXI, and SfiI. Both full-length light-chain and variable domain of heavy-chain genes were inserted into the vector in one step by four-way ligation, and full-length bivalent antibodies were displayed on mammalian cell…
A unique four-way ligation strategy was developed for rapid construction of a full-length antibody library. A mammalian expression vector was constructed that contained dual mammalian expression cassettes and sequences recognized by the unique restriction enzymes BsmBI, BstXI, and SfiI. Both full-length light-chain and variable domain of heavy-chain genes were inserted into the vector in one step by four-way ligation, and full-length bivalent antibodies were displayed on mammalian cell surfaces. Using this strategy, only 2 weeks were required to successfully construct high-quality, full-length human antibody libraries.
Other authors
Projects
-
Mind Mentor (2013 Health 2.0 Code-a-Thon Winner)
- Present
Despite the ready availability of health-tracking applications, few programs provide a fully integrated platform for monitoring both physical and emotional health.
Leveraging the built-in Validic API and psychiatric diagnostic testing based on the DSM-5, Mind Mentor provides a safe, user-friendly environment for patient-centric health evaluation.
From the administrative suite, doctors can schedule psychiatric appointments, therapy activities, create medication reminders, and…Despite the ready availability of health-tracking applications, few programs provide a fully integrated platform for monitoring both physical and emotional health.
Leveraging the built-in Validic API and psychiatric diagnostic testing based on the DSM-5, Mind Mentor provides a safe, user-friendly environment for patient-centric health evaluation.
From the administrative suite, doctors can schedule psychiatric appointments, therapy activities, create medication reminders, and monitor their patients’ health.
Patients are empowered by continual reaffirmation, staying connected to their doctor, and by witnessing their own emotional growth.Other creatorsSee project
Honors & Awards
-
Be a Venture Capitalist Case Competition
-
First Place
-
Deloitte Consulting Undergraduate Case Competition
-
First Place
-
Haas Undergraduate Leadership Award
-
Finalist
-
Jack Larson Center for Entrepreneurship
-
Jack Larson Fellow
Scholarship for Excellence in Entrepreneurship -
Phi Beta Lambda California State Case Competition
-
First Place
-
Siemens Competition in Math, Science, Technology
-
Semifinalist
Recommendations received
1 person has recommended Ivan
Join now to viewOther similar profiles
Explore more posts
-
Minh Q. Tran
How can combining investment discipline with operational execution change your startup's growth? At Mandalore Partners, we believe that capital alone isn't enough. The true challenge—and opportunity—lies in merging rigorous investment strategies with hands-on operational support. Consider this: many ventures receive funding but struggle to scale effectively because execution is left to chance. Our hybrid model bridges this gap by embedding operational expertise directly into the investment process. For example, we've partnered with fintech startups where strategic capital was complemented by active governance and execution support. This approach led to measurable growth—revenue increases of over 30% within 12 months—and sustainable scaling. What this means for founders and investors is clear: success is not just about securing funds but about how you apply them. A disciplined investment combined with operational rigor creates a foundation for long-term value. Are you ready to rethink how investment and execution can work together to accelerate your venture's potential? #VentureCapital #VentureCapitalAsAService #VCaaS
-
Arteen Arabshahi
SF VC Takeaway #2: Pricing expectations, performance bars, and what’s actually getting funded. One theme that came up repeatedly in SF was how far pricing expectations and performance bars have shifted, even compared to just a few years ago. A few things investors kept anchoring to: 1️⃣ Median Series A valuations are higher than their 2021 peaks, but fewer of them are getting done. 2️⃣ Capital is being concentrated into fewer and fewer companies (and lots of capital!) 3️⃣ “Good” progress is no longer enough and the bar for standout performance has moved in an AI-native world So what does “top performance” mean right now? One investor told me that top quartile seed companies in their portfolio are going from $0 to $2M in ARR in <12 months. Outside of pure traction numbers, a few other themes that came up to describe "top performance": 📈 Explosive early revenue ramps (or a very credible path to them) 📊 Strong velocity and momentum for 2 quarters in a row, even if the baseline is small. 🚀 Clear signals of category leadership, not just product-market fit. Sometimes shown by either domain expertise, speed of product optimization, or by lack of competition in the category. This creates a counterintuitive dynamic where it can be easier to fund a company with strong pedigrees in a hot space and no traction yet than a company that went from 0 to $1M ARR at what used to be considered a rapid pace. Pricing today is driven by trajectories, not moments in time. We used to say investors invest in lines not points; I think that's more true than ever now because crossing certain milestones doesn't carry as much influence as it once did. Finally, investors still say that valuation matters, but many of them are acting differently. Pace and belief in category-defining companies really sets the price; while slower growth gets scrutinized rather than discounted. One silver lining in the camp of durable growth: Series A rounds are happening so fast that many companies don’t yet have meaningful history of retention data. Large bets are being made on velocity before the durability is proven. Several investors told me the same thing: we may soon swing back to a market where retention, not growth, becomes the defining metric. Let's hope so. I'll share my third SF VC takeaway tomorrow!
7 Comments
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content